Sezary syndrome
Information
- Disease name
- Sezary syndrome
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04312841 | Active, not recruiting | Phase 2 | Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab | September 15, 2020 | December 31, 2024 |
| NCT03695471 | Active, not recruiting | Phase 2 | Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides | December 20, 2018 | October 11, 2024 |
| NCT02953301 | Active, not recruiting | Phase 2 | Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) | November 2016 | June 2024 |
| NCT02978625 | Active, not recruiting | Phase 2 | Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers | September 27, 2017 | September 1, 2025 |
| NCT04541017 | Active, not recruiting | Phase 1/Phase 2 | Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment | April 6, 2021 | June 30, 2025 |
| NCT04955340 | Completed | Phase 1 | A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat | October 12, 2021 | January 19, 2022 |
| NCT00177190 | Completed | In Vitro Evaluation of Immune Responses in Cutaneous T-Cell Lymphoma (CTCL) | June 2002 | January 2006 | |
| NCT00050999 | Completed | Phase 4 | Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients | June 1995 | December 2006 |
| NCT00178841 | Completed | Phase 2 | Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL | June 2005 | March 2007 |
| NCT00254332 | Completed | Effect of Denileukin Diftitox on Immune System in CTCL Patients | November 2005 | September 2007 | |
| NCT00611208 | Completed | Phase 2 | A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL) | January 2008 | November 2016 |
| NCT00748319 | Completed | N/A | Killer Immunoglobulin-Like Receptor Transcripts Expression for the Diagnosis of Epidermotropic Cutaneous T Cell Lymphoma | March 2009 | December 2011 |
| NCT00896493 | Completed | Phase 2 | Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma | May 2009 | December 2022 |
| NCT01134341 | Completed | Phase 1 | Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma | March 2010 | August 2015 |
| NCT01396070 | Completed | Phase 2 | Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level | May 2011 | May 2016 |
| NCT02652715 | Completed | N/A | Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma | January 19, 2016 | November 12, 2019 |
| NCT04185220 | Completed | Phase 1 | Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome | February 26, 2020 | May 18, 2022 |
| NCT00051012 | Completed | Phase 4 | Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients | September 1995 | December 2006 |
| NCT00091559 | Completed | Phase 2 | Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001) | February 3, 2005 | March 13, 2006 |
| NCT00099593 | Completed | Phase 2 | Immunization Against Tumor Cells in Sezary Syndrome | September 2004 | September 2007 |
| NCT00047060 | Completed | Phase 1/Phase 2 | Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome | July 30, 2002 | January 24, 2019 |
| NCT03905135 | Completed | Phase 1 | Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies | June 7, 2019 | May 17, 2022 |
| NCT05978141 | Recruiting | A Registry for People With T-cell Lymphoma | July 27, 2023 | July 27, 2030 | |
| NCT00177268 | Recruiting | Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research | October 2004 | January 2032 | |
| NCT03011814 | Recruiting | Phase 1/Phase 2 | Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma | March 8, 2017 | June 1, 2026 |
| NCT03587844 | Recruiting | Phase 2 | Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients | July 3, 2018 | July 2025 |
| NCT03602157 | Recruiting | Phase 1 | Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL | December 12, 2018 | September 30, 2041 |
| NCT03646422 | Recruiting | AEDV Registry of Primary Cutaneous Lymphoma | September 1, 2016 | January 1, 2025 | |
| NCT04930653 | Recruiting | Phase 2 | Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma | October 19, 2022 | May 16, 2025 |
| NCT04960618 | Recruiting | Phase 2 | Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome | October 1, 2021 | July 2025 |
| NCT05157581 | Recruiting | Extracorporeal Photopheresis in Sezary Syndrome | April 4, 2023 | December 2026 | |
| NCT05377827 | Recruiting | Phase 1 | Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies | October 10, 2023 | April 30, 2026 |
| NCT05879458 | Recruiting | Phase 2 | Ritlecitinib in CTCL | May 17, 2023 | April 2026 |
| NCT05944562 | Recruiting | Phase 1 | Tulmimetostat (CPI-0209) in Patients With Mycosis Fungoides and Sézary Syndrome | January 9, 2024 | January 31, 2030 |
| NCT04256018 | Recruiting | Phase 2 | Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome | March 30, 2020 | August 2024 |
| NCT04676087 | Recruiting | Phase 1/Phase 2 | Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides | April 21, 2021 | April 28, 2025 |
| NCT04904146 | Recruiting | Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome. | April 2, 2021 | April 2027 | |
| NCT00127881 | Terminated | Phase 3 | Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome | July 2005 | |
| NCT02341209 | Terminated | Phase 2 | Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma | February 6, 2018 | February 6, 2021 |
| NCT01625455 | Terminated | Phase 4 | Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome | February 2012 | July 2016 |
| NCT00157274 | Unknown status | Phase 2 | Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome | July 2005 | July 2008 |
| NCT05206045 | Unknown status | Evolution of the SURvival of Patients With SEzary Syndrome (SS) Over the 1998-2020 Period and Its Association With the Early Use of Therapeutic Monoclonal Antibodies | January 2022 | June 30, 2022 | |
| NCT03373305 | Withdrawn | Phase 1 | Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas | March 2019 | April 26, 2019 |
- MeSH unique ID (MeSH (Medical Subject Headings))
- D012751